Use of antithrombotic drugs in the treatment of acute ischemic stroke: a survey of neurologists in practice in the United States.
In an attempt to determine the opinions and practices of neurologists regarding the use of antithrombotic drugs in the treatment of acute ischemic stroke, we conducted a survey of 349 randomly selected neurologists from throughout the United States. Responses were received from 247 (71%), and 219 identified themselves as primary or consulting physicians for patients with acute ischemic stroke. During the previous 12 months, these 219 physicians estimated that they had seen a total of 14,636 patients within 24 hours of acute ischemic stroke, and 22% of these patients were treated with heparin. The most frequently reported indications were prevention of recurrent cerebral embolism (82% of physicians) and progressing stroke (70%). Despite the frequent use of heparin, only 6.4% of neurologists felt that it has been shown to be effective, and 16.4% felt that it has been shown to be of no value. The primary concern about the use of heparin was lack of proven efficacy in 48% and safety concerns in 41%. Results of a future trial testing the efficacy of antithrombotic drugs would be useful for most neurologists in their management of patients with acute or progressing ischemic stroke.
Marsh
E E
EE
Department of Neurology, University of Iowa College of Medicine, Iowa City.
Adams
H P
HP
Biller
J
J
Wasek
P
P
Banwart
K
K
Mitchell
V
V
Woolson
R
R
D000208:Acute Disease; D002545:Brain Ischemia / Q000188:drug therapy*; D002544:Cerebral Infarction / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D003625:Data Collection; D005069:Evaluation Studies as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009462:Neurology / Q000379:methods*; D014481:United States
D005343:Fibrinolytic Agents; D006493:Heparin